1. Generics Bulletin
  2. >>Business
  3. >>Deals

Winlevi Attracts Interest From Multiple Industry Players

Canadian Launch From Sun Accompanied By Fresh Deals With Glenmark And Hikma

 
• By Dave Wallace

As Sun Pharma announces a Canadian launch for its licensed Winlevi clascoterone cream dermatology asset, the firm’s originating partner Cassiopea has struck further deals with Hikma and Glenmark for the acne treatment to be sold in Europe, the MENA region and South Africa.

Handshake
Deals have taken place around the globe for Winlevi

Fresh deals with off-patent industry players Glenmark and Hikma have been seen for Cassiopea’s Winlevi (clascoterone) acne treatment, in Europe and South Africa and in the Middle East and North Africa region respectively, at the same time as existing North America licensee Sun Pharma announced a launch in Canada.

Sun has enjoyed rights to Winlevi for some time, entering into a partnership with Italy’s Cassiopea back in 2021 to market the clascoterone 1%

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business